Evidence map›Paper›PMID 28768490›Full record

ArticleBMC cancer2017

Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?

Weiwei Zhao, Peng Wang, Huixun Jia, Menglei Chen, Xiaoli Gu, Minghui Liu, Zhe Zhang, Wenwu Cheng, Zhenyu Wu

Abstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiwei ZhaoDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Peng WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Huixun JiaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Menglei ChenDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoli GuDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Minghui LiuDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhe ZhangDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenwu ChengDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China. cwwxxm@sina.com.
Zhenyu WuDepartment of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, China. zyw@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lymphocytes played an important role in the natural history of cancer. The aim of this study was to explore the prognostic value of lymphocyte count and percentage for survival in advanced cancer patients receiving palliative care.

methodsA retrospective review of clinicopathological data from 378 consecutive advanced cancer patients and 106 extended follow-up patients treated with palliative care was conducted. Kaplan-Meier curves and multivariate cox regression analyses were used to evaluate the relationships of peripheral lymphocyte count (LC) and lymphocyte to white blood cell ratio (LWR) with overall survival (OS).

resultsThe median values for pretreatment LC and LWR were 1.1 (IQR, 0.8 ~ 1.5 × 10

conclusionsOur findings demonstrate that measurement of the dynamic changes of LWR prior to treatment and during follow-up may represent a simple and new powerful prognostic factor for patients with advanced cancer, unlike measurement of LC. As a bedside marker of immune status, the prognostic role of LWR should be further evaluated in prospective studies.

Indexed as

Lymphocyte CountAgedComorbidityFemaleHumansKaplan-Meier EstimateLeukocyte CountMaleMiddle AgedNeoplasmsNeoplasm StagingPalliative CarePrognosisProportional Hazards ModelsRisk FactorsAdvanced cancerLymphocyte countLymphocyte to white blood cell ratioPalliative carePrognostic value

Identifiers

PMID28768490
PMCPMC5541405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.